Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 1481-1490 of 2905 for cancer

Edit search filters
  1. A Study To Evaluate CC-96191 To Treat Participants With Relapsed Or Refractory Acute Myeloid Leukemia

    Jacksonville, FL, Rochester, MN

  2. A Study Of MT-0169 In Participants With Relapsed Or Refractory Multiple Myeloma Or Non-Hodgkin Lymphoma

    Jacksonville, FL, Rochester, MN

  3. GB5121 In Adult Subjects With Relapsed/Refractory CNS Lymphoma

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  4. A Study To Evaluate MEDI2228 In Subjects With Relapsed/ Refractory Multiple Myeloma

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  5. A Trial Of The FMS-like Tyrosine Kinase 3 (FLT3) Inhibitor Gilteritinib Administered As Maintenance Therapy Following Allogeneic Transplant For Patients With FLT3/Internal Tandem Duplication (ITD) Acute Myeloid Leukemia (AML)

    Scottsdale/Phoenix, AZ, Rochester, MN

  6. Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine As First-Line Treatment For Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), Or Low-Blast Acute Myelogenous Leukemia (AML)

    Jacksonville, FL

  7. A Study Of AO-176 As Monotherapy Combinated With Bortezomib And Dexamethasone In Adults With Relapsed Or Refractory Multiple Myeloma

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  8. Cyclophosphamide, Ixazomib, And Dexamethasone In Treating Patients With Previously Untreated Symptomatic Multiple Myeloma

    Scottsdale/Phoenix, AZ, Rochester, MN

  9. Lenalidomide Plus Rituximab Followed By Lenalidomide Versus Rituximab Maintenance For Relapsed/Refractory Follicular, Marginal Zone Or Mantle Cell Lymphoma.

    Rochester, MN

  10. Study Of Orally Administered AG-120 In Subjects With Advanced Hematologic Malignancies With An IDH1 Mutation

    Scottsdale/Phoenix, AZ, Jacksonville, FL

.

Mayo Clinic Footer